MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) from its SEC filings: 2025 revenue $958.4 million (+432% vs the year before), net margin -30%, free cash flow -$190.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $958.4 million |
| Revenue growth | +432% |
| Net income | -$288.3 million |
| Net margin | -30.1% |
| Free cash flow | -$190.0 million |
| Diluted EPS | $-10.15 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +71% |
| Cash | $292.7 million |
| Long-term debt | $340.8 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.